Subscribe for great stories in your community!
King of Prussia’s biotherapeutics company CSL Behring is acquiring Calimmune, a clinical-stage biotechnology company, for $91 million, writes Linda Loyd for Philly.com…
Before we send you to this site, please subscribe to our daily newsletter.
